.png){kind=icon}
.png){kind=icon}
Return
HERMES-24 score for outcome prediction in large vessel occlusion stroke: Real-world data from the Austrian stroke network
.png){kind=icon}
PRE
AI
T
D
S
H
M
A
E
B
S
J
L
P
M
P
R
M
J
C
C
M
DOI：10.1177/17474930261463018.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>The HERMES-24 score has recently been proposed to estimate the 90-day outcome in patients with anterior circulation large vessel occlusion (LVO) stroke.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Aim:</jats:title>
<jats:p>We aimed to further validate the HERMES-24 score in a real-world setting of LVO patients who had received endovascular stroke treatment (EVT).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>We used data of consecutive LVO patients treated with EVT in six Austrian stroke centers. The performance of the HERMES-24 score for outcome prediction at 90 days (modified Rankin Scale (mRS)) was investigated in predefined subgroups of anterior and vertebrobasilar LVO and within or beyond 6 h/unknown time windows.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>We analyzed 1571 patients with available 90-day follow-up. The HERMES-24 score was predictive of 90-day mRS ⩽ 2 for the total cohort, those with anterior LVO <6 h, anterior LVO ⩾6 h/unknown, vertebrobasilar LVO < 6 h, and vertebrobasilar LVO ⩾ 6 h/unknown with c-statistics (95% confidence interval (CI)) 0.90 (0.88–0.92), 0.90 (0.88–0.92), 0.89 (0.86–0.92), 0.88 (0.79–0.98) and 0.98 (0.96–1.0), respectively. The HERMES-24 score also yielded excellent outcome prediction for 90-day mRS ⩽ 3, an ordinal mRS, and mortality in all subgroups (c-statistics: 0.83–0.99).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>The HERMES-24 score is highly predictive for 90-day outcome in real-world patients with LVO stroke treated with EVT regardless of LVO localization or symptom onset to treatment time.</jats:p>
</jats:sec>
Journal
IF:
8.7
Papers:
3.0K
Citations:
8.4K
Organization
Cited Papers